Literature DB >> 15964291

Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.

Ian S Fraser1, Edith Weisberg, Vivian Brache, Francisco Alvarez, Rebeca Massai, Daniel R Mishell, Dan Apter, Judi Gale, Yun Yen Tsong, Irving Sivin.   

Abstract

OBJECTIVES: This trial tested the hypothesis that menstrually signaled use of contraceptive vaginal rings ("rings") releasing low-dose combinations of Nestorone (NES) and ethinyl estradiol (EE) would reliably suppress luteal activity and ovulation, and prevent unintended pregnancy, while controlling the incidence of menstrual bleeding episodes and bleeding days.
METHODS: Nestorone/ethinyl estradiol rings releasing 50/10, 50/20 and 150/15 mug/day were studied through 6 months. A ring was to be used continuously, until its removal was signaled by menstrual bleeding. Reinsertion was required 96 h after removal. Serum for NES, EE and progesterone were collected and assayed, and vaginal ultrasound scans were performed in three 5-week periods to examine luteal activity, follicular growth, ovulation and their correlates. In 10 subjects using the 150/15 ring, six samples were drawn in the 24-h period after ring removal to examine serum levels of NES and EE.
RESULTS: One hundred sixty subjects at three doses provided blood samples. Median serum concentrations of NES and EE demonstrated dose ratios slightly below the nominal dose ratios expected. Serum NES concentrations declined 19-22% from weeks 3 to 25. Changes in EE levels depended on dose. Nestorone levels fell 81% by 24 h after ring removal and EE levels fell by 50%. Luteal activity was completely suppressed in 94-95% of cycles and in 90% of subjects. Three pregnancies occurred in subjects participating in this serum sampling study.
CONCLUSION: Satisfactory serum levels of NES and EE, and a high level of ovulation suppression were achieved. Irregular ring use, however, permitted pregnancies to occur.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964291     DOI: 10.1016/j.contraception.2004.12.015

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Authors:  J T Jensen; A B Edelman; B A Chen; D F Archer; K T Barnhart; M A Thomas; A E Burke; C L Westhoff; L S Wan; R Sitruk-Ware; N Kumar; B Variano; D L Blithe
Journal:  Contraception       Date:  2018-02-02       Impact factor: 3.375

2.  Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.

Authors:  Vivian Brache; Regine Sitruk-Ware; Alistair Williams; Diana Blithe; Horacio Croxatto; Narender Kumar; Sushma Kumar; Yun-Yen Tsong; Irving Sivin; Anita Nath; Heather Sussman; Leila Cochon; Maria Jose Miranda; Verónica Reyes; Anibal Faundes; Daniel Mishell
Journal:  Contraception       Date:  2011-12-15       Impact factor: 3.375

3.  Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men.

Authors:  Vahid Mahabadi; John K Amory; Ronald S Swerdloff; William J Bremner; Stephanie T Page; Regine Sitruk-Ware; Peter D Christensen; Narender Kumar; Yun-Yen Tsong; Diana Blithe; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

Review 4.  Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.

Authors:  Alison Edelman; Elizabeth Micks; Maria F Gallo; Jeffrey T Jensen; David A Grimes
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

Review 5.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

6.  Vaginal rings for delivery of HIV microbicides.

Authors:  R Karl Malcolm; Susan M Fetherston; Clare F McCoy; Peter Boyd; Ian Major
Journal:  Int J Womens Health       Date:  2012-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.